KalVista Pharmaceuticals, Inc. (KALV) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
Analysis Summary
Trailing-twelve-month margins: gross margin 92.0%, operating margin -120.8%, net margin -119.4%.
At the current price of $27.00, KALV has negative trailing earnings (P/E not meaningful) and an ROE of -10.57%. Market capitalisation stands at $1.4B.
Balance sheet quality for KALV: current ratio of 5.6, net cash position of $148.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $27.00 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -503.31 |
| EV / EBITDA | -12.74 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1057.44% |
| Return on Invested Capital | -46.81% |
| Return on Assets | -41.28% |
| Gross Margin | 92.03% |
| Operating Margin | -120.80% |
| Net Margin | -119.44% |
Financial Health
| Debt / Equity | -104.83 |
| Current Ratio | 5.58 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | $1.4B | -10.6% | ||
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| PTGX | Protagonist Therapeutics, Inc. | $9.2B | 8.71 | -21.2% | |
| COGT | Cogent Biosciences, Inc. | $5.7B | 10.45 | -72.6% | |
| SRRK | Scholar Rock Holding Corporation | $5.9B | 22.93 | -160.2% | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | 70.23 | 8.91 | 13.7% |
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +67.18% |
| 1 year | +101.79% |
| 3 years | +175.51% |
| 5 years | +40.26% |
52-Week Range
| 52-week High | $27.00 |
| 52-week Low | $9.83 |
| Avg Volume (90d) | 2.7M |
Related companies: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explore sector: Healthcare · Biotechnology
More sections of KALV: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks